ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
1. Introduction Lung cancer represents the leading cause of cancer deaths worldwide, with more than 1.8 million deaths in 2020 [1]; 85% are non-small-cell lung cancers (NSCLCs) and 25% of them …
Advances and future directions in ROS1 fusion-positive lung cancer
Aug 23, 2024 · Understanding of the biology of ROS1 fusion-positive (ROS1+) non–small cell lung cancer (NSCLC) and treatment approaches has progressed immensely over the past decades, …
Current Targeted Therapy Options in ROS1-Positive NSCLC
Oct 23, 2024 · ROS1 rearrangements in NSCLC are rare but significant, often leading to brain metastases and poor prognosis. ROS1-targeted therapies are preferred over immune checkpoint …
Array of Agents Allow for Treatment Individualization in ROS1+ NSCLC
Jul 27, 2025 · Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.
What do the new guidelines mean for ROS1-fusion positive and ALK ...
Aug 8, 2025 · An overview of guideline changes for ROS1-fusion positive & ALK-positive non-small cell lung cancer. Uncover how your treatment may change.
JNCCN 360 - Non–Small Cell Lung Cancer - Repotrectinib for <em>ROS1…
Dec 6, 2024 · Efforts to improve the management of locally advanced and metastatic ROS1 fusion–positive non–small cell lung cancer (NSCLC) have resulted in significantly improved new …
New treatment for ROS1+ non-small cell lung cancer
Jun 25, 2025 · The good news The U.S. Food and Drug Administration (FDA) approved taletrectinib for adults with locally advanced or metastatic ROS1-positive (+) non-small cell lung cancer (NSCLC). …
FDA Approves Taletrectinib for ROS1-Positive NSCLC Treatment
Jun 13, 2025 · In non-small cell lung cancer (NSCLC), ROS1 gene rearrangements result in the formation of fusion proteins that drive constitutive activation of the ROS1 kinase domain.
Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI
Feb 16, 2024 · Expanding treatment options for advanced lung cancers with ROS1 fusions ROS1 fusions occur when part of the gene breaks off and attaches to another gene. In lung cancer cells …
Advances and future directions in ROS1 fusion-positive lung cancer
Nov 4, 2024 · Abstract ROS1 gene fusions are an established oncogenic driver comprising 1%-2% of non-small cell lung cancer (NSCLC). Successful targeting of ROS1 fusion oncoprotein with oral small …